Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Acquisitions & Divestments (2021 - 2025)

Historic Change in Acquisitions & Divestments for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $42.4 million.

  • Prime Medicine's Change in Acquisitions & Divestments fell 3078.14% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.6 million, marking a year-over-year decrease of 5906.46%. This contributed to the annual value of $204.2 million for FY2024, which is 5404.81% up from last year.
  • As of Q3 2025, Prime Medicine's Change in Acquisitions & Divestments stood at $42.4 million, which was down 3078.14% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Change in Acquisitions & Divestments registered a high of $72.5 million during Q1 2024, and its lowest value of $3.0 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $31.2 million (2022), whereas its average is $31.2 million.
  • Per our database at Business Quant, Prime Medicine's Change in Acquisitions & Divestments soared by 23368.33% in 2023 and then plummeted by 9586.21% in 2025.
  • Over the past 5 years, Prime Medicine's Change in Acquisitions & Divestments (Quarter) stood at $13.0 million in 2021, then skyrocketed by 92.31% to $25.0 million in 2022, then skyrocketed by 90.14% to $47.5 million in 2023, then plummeted by 30.79% to $32.9 million in 2024, then rose by 28.97% to $42.4 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $42.4 million for Q3 2025, versus $11.2 million for Q2 2025 and $3.0 million for Q1 2025.